Spexis Past Earnings Performance
Past criteria checks 0/6
Spexis's earnings have been declining at an average annual rate of -44.3%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 76.7% per year.
Key information
-44.3%
Earnings growth rate
-6.9%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 76.7% |
| Return on equity | -857.5% |
| Net Margin | -3,295.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Spexis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -20 | 9 | 12 |
| 30 Sep 23 | 1 | -16 | 8 | 10 |
| 30 Jun 23 | 1 | -12 | 6 | 9 |
| 31 Mar 23 | 1 | -16 | 7 | 11 |
| 31 Dec 22 | 1 | -19 | 7 | 13 |
| 30 Sep 22 | 1 | -20 | 7 | 10 |
| 30 Jun 22 | 1 | -21 | 7 | 7 |
| 31 Mar 22 | 0 | -16 | 5 | 4 |
| 31 Dec 21 | 0 | -12 | 3 | 1 |
| 30 Sep 21 | 0 | -7 | 2 | 1 |
| 30 Jun 21 | 0 | -2 | 1 | 1 |
| 31 Mar 21 | 0 | -2 | 1 | 1 |
| 31 Dec 20 | 0 | -2 | 1 | 1 |
| 31 Dec 19 | 0 | -2 | 1 | 0 |
Quality Earnings: SPEXZ is currently unprofitable.
Growing Profit Margin: SPEXZ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SPEXZ is unprofitable, and losses have increased over the past 5 years at a rate of 44.3% per year.
Accelerating Growth: Unable to compare SPEXZ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SPEXZ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.8%).
Return on Equity
High ROE: SPEXZ has a negative Return on Equity (-857.53%), as it is currently unprofitable.